| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Stromal Tumors | 61 | 2024 | 615 | 10.920 |
Why?
|
| Leiomyosarcoma | 32 | 2024 | 424 | 8.140 |
Why?
|
| Sarcoma | 31 | 2024 | 1786 | 4.240 |
Why?
|
| Gastrointestinal Neoplasms | 23 | 2024 | 951 | 3.100 |
Why?
|
| Uterine Neoplasms | 22 | 2023 | 1434 | 3.060 |
Why?
|
| Pyrroles | 26 | 2024 | 1137 | 3.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 27 | 2024 | 729 | 2.900 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 15 | 2024 | 367 | 2.740 |
Why?
|
| Naphthyridines | 9 | 2024 | 141 | 2.440 |
Why?
|
| Urea | 9 | 2024 | 445 | 2.220 |
Why?
|
| Triazines | 7 | 2024 | 310 | 1.950 |
Why?
|
| Protein Kinase Inhibitors | 35 | 2024 | 5640 | 1.870 |
Why?
|
| Liposarcoma | 4 | 2024 | 283 | 1.750 |
Why?
|
| Soft Tissue Neoplasms | 11 | 2022 | 1151 | 1.640 |
Why?
|
| Antineoplastic Agents | 33 | 2024 | 13629 | 1.510 |
Why?
|
| Indoles | 20 | 2023 | 1830 | 1.430 |
Why?
|
| Carbolines | 2 | 2024 | 288 | 1.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11708 | 1.310 |
Why?
|
| Piperazines | 19 | 2023 | 2520 | 1.250 |
Why?
|
| Phenylurea Compounds | 12 | 2022 | 529 | 1.210 |
Why?
|
| Doxorubicin | 9 | 2024 | 2207 | 1.130 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2024 | 5230 | 1.090 |
Why?
|
| Pyrazoles | 7 | 2024 | 1992 | 1.080 |
Why?
|
| Pyrimidines | 18 | 2023 | 3011 | 1.070 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2020 | 329 | 0.930 |
Why?
|
| Benzamides | 18 | 2023 | 1369 | 0.890 |
Why?
|
| Hemangiosarcoma | 3 | 2024 | 218 | 0.880 |
Why?
|
| Ketones | 1 | 2024 | 183 | 0.850 |
Why?
|
| Furans | 1 | 2024 | 199 | 0.850 |
Why?
|
| Aminopyridines | 2 | 2024 | 564 | 0.820 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 306 | 0.750 |
Why?
|
| Purines | 1 | 2024 | 601 | 0.710 |
Why?
|
| Pyridazines | 1 | 2022 | 200 | 0.710 |
Why?
|
| Mutation | 27 | 2024 | 29950 | 0.680 |
Why?
|
| Exons | 3 | 2024 | 2391 | 0.670 |
Why?
|
| Pyridines | 10 | 2021 | 2877 | 0.640 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2019 | 2415 | 0.630 |
Why?
|
| Immunoconjugates | 2 | 2023 | 949 | 0.620 |
Why?
|
| Disease-Free Survival | 19 | 2017 | 6830 | 0.560 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2017 | 46 | 0.540 |
Why?
|
| Uterus | 1 | 2020 | 651 | 0.540 |
Why?
|
| 14-3-3 Proteins | 1 | 2017 | 221 | 0.520 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2016 | 125 | 0.520 |
Why?
|
| Leukemia | 1 | 2023 | 1522 | 0.500 |
Why?
|
| Deoxycytidine | 5 | 2019 | 872 | 0.490 |
Why?
|
| Maximum Tolerated Dose | 5 | 2024 | 877 | 0.480 |
Why?
|
| Vascular Neoplasms | 2 | 2014 | 167 | 0.470 |
Why?
|
| Humans | 154 | 2024 | 760261 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2023 | 9274 | 0.460 |
Why?
|
| Extremities | 2 | 2020 | 867 | 0.460 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2019 | 380 | 0.450 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2022 | 3217 | 0.450 |
Why?
|
| Treatment Outcome | 36 | 2024 | 64947 | 0.450 |
Why?
|
| Genes, Retinoblastoma | 1 | 2014 | 125 | 0.450 |
Why?
|
| Neoplasms | 12 | 2023 | 22066 | 0.450 |
Why?
|
| Neoplasm Metastasis | 9 | 2024 | 4891 | 0.440 |
Why?
|
| Aromatase Inhibitors | 2 | 2014 | 511 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 586 | 0.420 |
Why?
|
| Vena Cava, Inferior | 2 | 2014 | 458 | 0.420 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2024 | 2058 | 0.420 |
Why?
|
| Salvage Therapy | 1 | 2019 | 1266 | 0.420 |
Why?
|
| Drug Administration Schedule | 10 | 2021 | 4900 | 0.410 |
Why?
|
| Adult | 78 | 2024 | 219847 | 0.410 |
Why?
|
| Middle Aged | 77 | 2024 | 220175 | 0.400 |
Why?
|
| Nitriles | 2 | 2014 | 955 | 0.390 |
Why?
|
| Aged | 62 | 2024 | 168995 | 0.380 |
Why?
|
| Triazoles | 2 | 2014 | 904 | 0.380 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 311 | 0.380 |
Why?
|
| Female | 95 | 2024 | 391011 | 0.380 |
Why?
|
| Endometrial Neoplasms | 3 | 2018 | 1361 | 0.380 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1115 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 6545 | 0.370 |
Why?
|
| Irritants | 1 | 2009 | 43 | 0.340 |
Why?
|
| Sarcoma, Alveolar Soft Part | 2 | 2023 | 43 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2805 | 0.340 |
Why?
|
| Dioxoles | 1 | 2009 | 95 | 0.330 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2009 | 81 | 0.330 |
Why?
|
| Pleural Neoplasms | 1 | 2014 | 609 | 0.320 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1122 | 0.320 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 4312 | 0.310 |
Why?
|
| Skin Ulcer | 1 | 2009 | 129 | 0.310 |
Why?
|
| Medical Oncology | 4 | 2023 | 2321 | 0.300 |
Why?
|
| Soft Tissue Injuries | 1 | 2009 | 172 | 0.300 |
Why?
|
| Mesentery | 1 | 2008 | 203 | 0.300 |
Why?
|
| Combined Modality Therapy | 10 | 2021 | 8551 | 0.290 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 9388 | 0.290 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2014 | 1207 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 3 | 2014 | 706 | 0.290 |
Why?
|
| Estrogens | 1 | 2014 | 1520 | 0.280 |
Why?
|
| Electron Transport Complex II | 3 | 2019 | 53 | 0.280 |
Why?
|
| Male | 66 | 2024 | 359413 | 0.280 |
Why?
|
| Bone Neoplasms | 5 | 2022 | 2532 | 0.270 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2202 | 0.250 |
Why?
|
| Hysterectomy | 4 | 2015 | 901 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 9196 | 0.250 |
Why?
|
| Melanoma | 1 | 2023 | 5695 | 0.240 |
Why?
|
| Imidazoles | 2 | 2022 | 1178 | 0.240 |
Why?
|
| Neoplasm Staging | 12 | 2022 | 11141 | 0.240 |
Why?
|
| Prognosis | 18 | 2022 | 29636 | 0.240 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2024 | 53 | 0.230 |
Why?
|
| Leiomyoma | 3 | 2021 | 654 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1060 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2012 | 2047 | 0.220 |
Why?
|
| Young Adult | 26 | 2024 | 58673 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 675 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 10829 | 0.200 |
Why?
|
| Pyrimidinones | 1 | 2024 | 383 | 0.200 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 1423 | 0.200 |
Why?
|
| Hypophosphatemia | 1 | 2022 | 93 | 0.200 |
Why?
|
| Aged, 80 and over | 27 | 2024 | 58947 | 0.190 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 275 | 0.190 |
Why?
|
| Receptors, CCR | 1 | 2021 | 37 | 0.190 |
Why?
|
| Inflammation | 1 | 2020 | 10757 | 0.180 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 221 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 544 | 0.170 |
Why?
|
| Adolescent | 24 | 2023 | 87747 | 0.170 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1395 | 0.170 |
Why?
|
| Benzenesulfonates | 2 | 2012 | 165 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.170 |
Why?
|
| Leukopenia | 1 | 2019 | 212 | 0.160 |
Why?
|
| Pyridones | 1 | 2024 | 788 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2235 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2015 | 886 | 0.160 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2010 | 178 | 0.160 |
Why?
|
| Genotype | 4 | 2022 | 12959 | 0.150 |
Why?
|
| Phthalazines | 2 | 2023 | 377 | 0.150 |
Why?
|
| Hypertension | 3 | 2012 | 8595 | 0.140 |
Why?
|
| Retrospective Studies | 18 | 2022 | 80301 | 0.140 |
Why?
|
| Survival Rate | 10 | 2020 | 12806 | 0.140 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 181 | 0.140 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4317 | 0.140 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2018 | 93 | 0.140 |
Why?
|
| Gene Duplication | 1 | 2018 | 314 | 0.140 |
Why?
|
| Haemophilus Vaccines | 4 | 1998 | 71 | 0.140 |
Why?
|
| Morpholines | 1 | 2020 | 583 | 0.140 |
Why?
|
| Osteosarcoma | 1 | 2022 | 898 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 243 | 0.130 |
Why?
|
| Vinblastine | 2 | 2008 | 487 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 2214 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 8058 | 0.130 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 11064 | 0.130 |
Why?
|
| Taxoids | 2 | 2017 | 668 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 429 | 0.130 |
Why?
|
| Succinate Dehydrogenase | 1 | 2016 | 145 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2016 | 193 | 0.130 |
Why?
|
| Research Design | 3 | 2021 | 6181 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 8984 | 0.130 |
Why?
|
| Antibodies | 1 | 2023 | 2424 | 0.120 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2016 | 67 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2020 | 1897 | 0.120 |
Why?
|
| Genomics | 3 | 2022 | 5790 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 72 | 0.120 |
Why?
|
| Ovariectomy | 2 | 2014 | 611 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1791 | 0.120 |
Why?
|
| Cancer Vaccines | 2 | 2015 | 1044 | 0.120 |
Why?
|
| Breast | 1 | 2023 | 1980 | 0.120 |
Why?
|
| Neutropenia | 1 | 2019 | 884 | 0.120 |
Why?
|
| Benzofurans | 1 | 2014 | 142 | 0.120 |
Why?
|
| Disease Management | 2 | 2021 | 2508 | 0.120 |
Why?
|
| Salpingectomy | 1 | 2014 | 48 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 3531 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3826 | 0.110 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39254 | 0.110 |
Why?
|
| Vaccines | 1 | 2022 | 833 | 0.110 |
Why?
|
| Sirolimus | 2 | 2011 | 1548 | 0.110 |
Why?
|
| Pyrazines | 1 | 2019 | 1200 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 13249 | 0.110 |
Why?
|
| Neoplasm Seeding | 1 | 2013 | 85 | 0.110 |
Why?
|
| Disease Progression | 6 | 2021 | 13505 | 0.110 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 4109 | 0.110 |
Why?
|
| Benzoquinones | 1 | 2013 | 198 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 220 | 0.110 |
Why?
|
| Survival Analysis | 6 | 2017 | 10185 | 0.100 |
Why?
|
| Stomatitis, Aphthous | 1 | 2013 | 52 | 0.100 |
Why?
|
| Diagnostic Imaging | 3 | 2016 | 3526 | 0.100 |
Why?
|
| Smooth Muscle Tumor | 1 | 2012 | 63 | 0.100 |
Why?
|
| Mediator Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
| Niacinamide | 2 | 2012 | 414 | 0.100 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 265 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3726 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2016 | 677 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 482 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1122 | 0.100 |
Why?
|
| Necrosis | 2 | 2022 | 1612 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 255 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 315 | 0.100 |
Why?
|
| Positron-Emission Tomography | 4 | 2014 | 6457 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 3 | 2018 | 2811 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 412 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2013 | 1790 | 0.090 |
Why?
|
| Nomograms | 1 | 2013 | 238 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2023 | 41317 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 749 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2012 | 302 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12532 | 0.090 |
Why?
|
| Connective Tissue | 2 | 2022 | 416 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 772 | 0.080 |
Why?
|
| Prospective Studies | 9 | 2022 | 54263 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2823 | 0.080 |
Why?
|
| Upper Extremity | 2 | 2012 | 661 | 0.080 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2009 | 101 | 0.080 |
Why?
|
| Fertility | 1 | 2014 | 772 | 0.080 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2008 | 21 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3618 | 0.080 |
Why?
|
| Stomatitis | 1 | 2011 | 271 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 2010 | 308 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2023 | 629 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 119 | 0.080 |
Why?
|
| Thiophenes | 1 | 2013 | 587 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 549 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 161 | 0.080 |
Why?
|
| Quinolines | 1 | 2013 | 759 | 0.070 |
Why?
|
| Haemophilus Infections | 2 | 1998 | 94 | 0.070 |
Why?
|
| History, 16th Century | 1 | 2007 | 70 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7468 | 0.070 |
Why?
|
| History, 17th Century | 1 | 2007 | 107 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 3483 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2014 | 2646 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2018 | 2978 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 933 | 0.070 |
Why?
|
| Phenotype | 2 | 2022 | 16543 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 20484 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 680 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 778 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 664 | 0.070 |
Why?
|
| Pedigree | 1 | 2014 | 4577 | 0.070 |
Why?
|
| Menopause | 1 | 2014 | 1640 | 0.070 |
Why?
|
| Hypothyroidism | 2 | 2011 | 665 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 685 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 619 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 4494 | 0.060 |
Why?
|
| Bacterial Vaccines | 3 | 1996 | 401 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2010 | 619 | 0.060 |
Why?
|
| Radiography | 2 | 2014 | 6965 | 0.060 |
Why?
|
| Proteinuria | 1 | 2008 | 594 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 3 | 1998 | 2696 | 0.060 |
Why?
|
| Polysaccharides, Bacterial | 3 | 1996 | 574 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 526 | 0.060 |
Why?
|
| Device Removal | 1 | 2009 | 634 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 666 | 0.060 |
Why?
|
| Apoptosis | 1 | 2020 | 9497 | 0.060 |
Why?
|
| Family Health | 1 | 2009 | 1258 | 0.060 |
Why?
|
| Drainage | 1 | 2009 | 1161 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2007 | 496 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 576 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2012 | 2141 | 0.050 |
Why?
|
| Telomerase | 1 | 2008 | 747 | 0.050 |
Why?
|
| G(M2) Ganglioside | 1 | 2022 | 15 | 0.050 |
Why?
|
| Age Factors | 2 | 2017 | 18415 | 0.050 |
Why?
|
| Europe | 2 | 2021 | 3433 | 0.050 |
Why?
|
| Vaccines, Conjugate | 4 | 1998 | 328 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 1723 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2022 | 183 | 0.050 |
Why?
|
| Consensus | 2 | 2022 | 3106 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2017 | 3840 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 2 | 2022 | 1041 | 0.050 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2003 | 169 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 12968 | 0.050 |
Why?
|
| Population Groups | 1 | 2022 | 211 | 0.050 |
Why?
|
| Tetanus Toxoid | 2 | 1998 | 193 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 17766 | 0.040 |
Why?
|
| Haplorhini | 1 | 2021 | 529 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2024 | 1066 | 0.040 |
Why?
|
| Asia | 1 | 2021 | 618 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2022 | 24086 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 346 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 6067 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7854 | 0.040 |
Why?
|
| Time Factors | 5 | 2021 | 40133 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 6855 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2003 | 963 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2012 | 8523 | 0.040 |
Why?
|
| Tetanus | 1 | 1998 | 51 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 556 | 0.040 |
Why?
|
| Constipation | 1 | 2023 | 561 | 0.040 |
Why?
|
| Child | 8 | 2022 | 79758 | 0.040 |
Why?
|
| Alberta | 1 | 2018 | 66 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2003 | 1246 | 0.040 |
Why?
|
| Alopecia | 1 | 2022 | 415 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 1998 | 180 | 0.040 |
Why?
|
| Hodgkin Disease | 2 | 1996 | 1381 | 0.040 |
Why?
|
| North America | 1 | 2021 | 1282 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 1995 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 1288 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 1998 | 225 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 21065 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2730 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 815 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2020 | 12412 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15273 | 0.030 |
Why?
|
| Biopsy | 2 | 2019 | 6775 | 0.030 |
Why?
|
| Japan | 1 | 2021 | 1369 | 0.030 |
Why?
|
| Quinazolines | 1 | 2023 | 1363 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2014 | 4044 | 0.030 |
Why?
|
| CHO Cells | 1 | 2019 | 1389 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1523 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2003 | 1180 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 2897 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2024 | 2861 | 0.030 |
Why?
|
| Fatigue | 2 | 2013 | 1544 | 0.030 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 380 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2138 | 0.030 |
Why?
|
| DNA Repair | 1 | 2023 | 2039 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 2015 | 158 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2003 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3804 | 0.030 |
Why?
|
| DNA Damage | 1 | 2023 | 2442 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 118 | 0.030 |
Why?
|
| Lower Extremity | 2 | 2012 | 1196 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 787 | 0.030 |
Why?
|
| Incidence | 3 | 2021 | 21378 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2013 | 161 | 0.030 |
Why?
|
| Animals | 6 | 2023 | 167940 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 600 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 5797 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1995 | 407 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3605 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1995 | 863 | 0.030 |
Why?
|
| Mice | 4 | 2023 | 81216 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 840 | 0.020 |
Why?
|
| Adolescent Medicine | 1 | 2012 | 73 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 628 | 0.020 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 104 | 0.020 |
Why?
|
| Asthenia | 1 | 2011 | 16 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2012 | 23363 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 15827 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 36247 | 0.020 |
Why?
|
| Quality of Life | 2 | 2023 | 13300 | 0.020 |
Why?
|
| Pathology, Clinical | 1 | 2015 | 375 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1996 | 503 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 10183 | 0.020 |
Why?
|
| Bacterial Capsules | 3 | 1996 | 242 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 423 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 1111 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3584 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 15680 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 1996 | 732 | 0.020 |
Why?
|
| Genetic Testing | 2 | 2014 | 3530 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 1996 | 1470 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7236 | 0.020 |
Why?
|
| United States | 4 | 2021 | 72363 | 0.020 |
Why?
|
| Erythema | 1 | 2011 | 262 | 0.020 |
Why?
|
| Rats | 2 | 2021 | 23695 | 0.020 |
Why?
|
| Gene Expression | 1 | 2022 | 7592 | 0.020 |
Why?
|
| Risk Factors | 5 | 2015 | 74269 | 0.020 |
Why?
|
| Depression | 1 | 2008 | 8033 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1843 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2010 | 466 | 0.020 |
Why?
|
| World Health Organization | 1 | 2014 | 1319 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 880 | 0.020 |
Why?
|
| Patients | 1 | 2014 | 906 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3618 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2012 | 1083 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 552 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 235 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 801 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1996 | 2314 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1436 | 0.020 |
Why?
|
| Thyroiditis | 1 | 2006 | 86 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 504 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1342 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2021 | 4361 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2021 | 3421 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 5039 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 938 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 1094 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 5784 | 0.020 |
Why?
|
| Risk | 2 | 2009 | 9629 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3145 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 2945 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16905 | 0.010 |
Why?
|
| Diarrhea | 1 | 2011 | 1341 | 0.010 |
Why?
|
| SEER Program | 1 | 2009 | 1532 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2009 | 965 | 0.010 |
Why?
|
| Mastectomy | 1 | 2012 | 1834 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2012 | 1666 | 0.010 |
Why?
|
| Clone Cells | 1 | 2007 | 1663 | 0.010 |
Why?
|
| Reoperation | 1 | 2013 | 4292 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 2906 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 11835 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1493 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2006 | 832 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18134 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2015 | 3903 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 1870 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 2 | 1996 | 397 | 0.010 |
Why?
|
| Recurrence | 1 | 2014 | 8487 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2012 | 2689 | 0.010 |
Why?
|
| Pregnancy | 2 | 2014 | 29725 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2016 | 4374 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6242 | 0.010 |
Why?
|
| Immunization | 2 | 1996 | 1228 | 0.010 |
Why?
|
| Wound Healing | 1 | 2012 | 2786 | 0.010 |
Why?
|
| Random Allocation | 2 | 1996 | 2394 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 2007 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11480 | 0.010 |
Why?
|
| Infant | 1 | 2022 | 36030 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2020 | 6797 | 0.010 |
Why?
|
| Skin | 1 | 2012 | 4468 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1884 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5201 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1998 | 4814 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3215 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22041 | 0.010 |
Why?
|
| Palliative Care | 1 | 2012 | 3607 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 5206 | 0.010 |
Why?
|
| Smoking | 1 | 2013 | 9070 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 14482 | 0.010 |
Why?
|
| Serotyping | 1 | 1996 | 324 | 0.010 |
Why?
|
| Meningococcal Vaccines | 1 | 1995 | 94 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 6310 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2007 | 5513 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1996 | 4546 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10434 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 2120 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2003 | 2544 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1998 | 42034 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 1402 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 10340 | 0.000 |
Why?
|
| Stroke | 1 | 2003 | 9945 | 0.000 |
Why?
|